Similarity and diversity of the tumor microenvironment in multiple metastases: Critical implications for overall and progression-free survival of high-grade serous ovarian cancer

Oncotarget

Volumn 7, Issue 44, 2016, Pages 71123-71135

  Heindl, Andreas ^a,b   Lan, Chunyan ^c   Rodrigues, Daniel Nava ^a   Koelble, Konrad ^a,b   Yuan, Yinyin ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Automated image analysis; Ecological diversity; High grade serous ovarian cancer; Locally advanced disease; Tumor microenvironment

Indexed keywords

ADULT; AGED; APPENDIX METASTASIS; ARTICLE; AUTOMATION; BLOOD CELL RATIO; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENTROPY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHOCYTE RATIO; MAJOR CLINICAL STUDY; MEAN LYMPHOCYTE RATIO; METASTASIS; OMENTUM METASTASIS; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM METASTASIS; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; SHANNON ENTROPY; SISTER MARY JOSEPH NODULE; SPLEEN METASTASIS; TUMOR MICROENVIRONMENT; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 84995395684     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12106     Document Type: Article

References (53)

1. Agarwal A, Tressel SL, Kaimal R, Balla M, Lam FH, Covic L, Kuliopulos A. Identification of a metalloproteasechemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res. 2010; 70: 5880-90
2. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013; 19: 961-8
3. Basanta D, Anderson ARA. Exploiting ecological principles to better understand cancer progression and treatment. Interface Focus. 2013; 3: 20130020
4. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 2013; 231: 21-34
5. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9: 415-28
6. Bowtell DD, Böhm S, Ahmed AA, Aspuria P-J, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015; 15: 668-79
7. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 2002; 20: 1248-1259
8. van der Burg MEL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S. The Effect of Debulking Surgery After Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer. Obstet Gynecol Surv. 1995; 50: 516-518
9. Burger, Robert A. and Brady, Mark F. and Bookman, Michael A. and Fleming, Gini F. and Monk, Bradley J. and Huang, Helen and Mannel, Robert S. and Homesley, Howard D. and Fowler, Jeffrey and Greer, Benjamin E. and Boente, Matthew and Birrer, Michael J. and SX. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med. 2011; 365: 2473-2483
10. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009; 114: 26-31
11. Chiva LM, Castellanos T, Alonso S, Gonzalez-Martin A. Minimal Macroscopic Residual Disease (0.1-1 cm). Is It Still a Surgical Goal in Advanced Ovarian Cancer? Int J Gynecol Cancer. 2016; 26: 906-911
12. Corvigno S, Wisman GBA, Mezheyeuski A, van der Zee AG, Nijman HW, Åvall-Lundqvist E, Östman A, Dahlstrand H. Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: inter-and intrapatient heterogeneity and impact on survival. Oncotarget. 2016; 7:18573-84. doi: 10.18632/oncotarget.7613
13. Cox DR. Regression Models and Life-Tables. J R Stat Soc Ser B. 1972; 34: 187-220
14. Daoust SP, Fahrig L, Martin AE, Thomas F. From forest and agro-ecosystems to the microecosystems of the human body: what can landscape ecology tell us about tumor growth, metastasis, and treatment options? Evol Appl. 2013; 6: 82-91
15. Dinh P, Harnett P, Piccart-Gebhart MJ, Awada A. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol. 2008; 67: 103-12
16. De Felice F, Marchetti C, Palaia I, Musio D, Muzii L, Tombolini V, Panici PB. Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. J Immunol Res. 2015; 2015: 1-7
17. Gatenby RA, Brown J, Vincent T. Lessons from Applied Ecology: Cancer Control Using an Evolutionary Double Bind. Cancer Res. 2009; 69: 7499-7502
18. Hoogstraat M, de Pagter MS, Cirkel GA, van Roosmalen MJ, Harkins TT, Duran K, Kreeftmeijer J, Renkens I, Witteveen PO, Lee CC, Nijman IJ, Guy T, van 't Slot R, et al. Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. Genome Res. 2014; 24: 200-11
19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 58: 71-96
20. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9: 239-52
21. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J. Am. Stat. Assoc
22. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007; 31: 161-9
23. Korolev KS, Xavier JB, Gore J. Turning ecology and evolution against cancer. Nat Rev Cancer. 2014; 14: 371-380
24. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang T-L, Shih I-M. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic highgrade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol. 2012; 226: 421-6
25. Lan C, Heindl A, Huang X, Xi S, Banerjee S, Liu J, Yuan Y. Quantitative histology analysis of the ovarian tumour microenvironment. Sci Rep. 2015; 5: 16317
26. Leong HS, Galletta L, Etemadmoghadam D, George J, Köbel M, Ramus SJ, Bowtell D. Efficient molecular subtype classification of high-grade serous ovarian cancer. J Pathol. 2015; 236: 272-7
27. Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W, Crum CP. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed). 2011; 3: 625-34
28. Morris EK, Caruso T, Buscot F, Fischer M, Hancock C, Maier TS, Meiners T, Müller C, Obermaier E, Prati D, Socher SA, Sonnemann I, Wäschke N, Wubet T, Wurst S, Rillig MC. Choosing and using diversity indices: insights for ecological applications from the German Biodiversity Exploratories. Ecol Evol. 2014; 4: 3514-24
29. Murakami R, Matsumura N, Mandai M, Yoshihara K, Tanabe H, Nakai H, Yamanoi K, Abiko K, Yoshioka Y, Hamanishi J, Yamaguchi K, Baba T, Koshiyama M, et al. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. Am. J. Pathol
30. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005; 5: 355-66
31. Natrajan R, Sailem H, Mardakheh FK, Arias Garcia M, Tape CJ, Dowsett M, Bakal C, Yuan Y. Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis. PLOS Med. 2016; 13: e1001961
32. Nawaz S, Yuan Y. Computational pathology: Exploring the spatial dimension of tumor ecology. Cancer Lett
33. Network TCGAR. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474: 609-15
34. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989; 8: 98-101
35. Park SY, Gönen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010; 120: 636-44
36. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 55: 74-108
37. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JYH, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 2013; 24: 751-65
38. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000; 92: 699-708
39. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001; 195: 451-6
40. Pienta KJ, McGregor N, Axelrod R, Axelrod DE. Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol. 2008; 1: 158-64
41. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009; 9: 285-93
42. Rosenberg MS. Handbook of spatial point-pattern analysis in ecology. Int J Geogr Inf Sci. 2015; 29: 1718-1719
43. Saitou M, Iida Y, Komazaki H, Narui C, Matsuno K, Kawabata A, Ueda K, Tanabe H, Takakura S, Isonishi S, Sasaki H, Okamoto A. Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer. Arch Gynecol Obstet. 2015; 291: 641-6
44. Schmid BC, Oehler MK. New perspectives in ovarian cancer treatment. Maturitas. 2014; 77: 128-36
45. Shannon CE. A mathematical theory of communication. ACM SIGMOBILE Mob Comput Commun Rev. 2001; 5: 3
46. Simpson EH. Measurement of Diversity. Nature. 1949; 163: 688-688
47. Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, Bear HD, Takabe K. Bevacizumab and breast cancer: what does the future hold? Future Oncol. 2012; 8: 403-14
48. Tothill RW, Tinker A V., George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew Y-E, et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome. Clin Cancer Res. 2008; 14: 5198-5208
49. Verhaak RGW, Tamayo P, Yang J-Y, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013; 123: 517-25
50. Winter WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25: 3621-7
51. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009; 9: 167-81
52. Yeung T-L, Leung CS, Wong K-K, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. TGFModulates Ovarian Cancer Invasion by Upregulating CAFDerived Versican in the Tumor Microenvironment. Cancer Res. 2013; 73: 5016-5028
53. Yuan Y, Failmezger H, Rueda OM, Ali HR, Gräf S, Chin S-F, Schwarz RF, Curtis C, Dunning MJ, Bardwell H, Johnson N, Doyle S, Turashvili G, Provenzano E, Aparicio S, Caldas C, Markowetz F. Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med. 2012; 4: 157ra143